Skip Over Navigation Links

Accelerating Medicines Partnership

Funding Initiatives

Alzheimer’s Disease

  • (No funding initiatives for Alzheimer’s disease are available at this time.)

Type 2 Diabetes

  • Limited Competition for the Data Coordinating Center of Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) — The purpose of this FOA is to solicit applications from the Program Director/Principal Investigator current awardee of the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Data Coordinating Center (DCC) (AMP T2D-GENES DCC). The AMP T2D-GENES consortium will consist of the DCC as well as participating sites being solicited by the companion FOA. The mission of AMP T2D-GENES is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants.
  • Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01) — This Funding Opportunity Announcement (FOA) invites applications for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (T2D-GENES) consortium. The AMP T2D-GENES will build on and expand the previous work of the T2D GENES consortium. The aim of the consortium is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants.

For more information about the FNIH RFPs, contact Sanya Fanous Whitaker, swhitaker@fnih.org.

Rheumatoid Arthritis and Lupus

  • Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Leadership Center (UM2) RFA-AR-14-015 — The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Leadership Center. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells.
  • Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis and Lupus: Network Research Sites (UH2/UH3) RFA-AR-14-016 — The purpose of this FOA is to solicit applications for the Accelerating Medicines Partnership (AMP) in Rheumatoid Arthritis (RA) and Lupus Network Research Sites. The AMP RA and Lupus Network is designed to ascertain and define shared and disease-specific biological pathways in order to identify relevant drug targets for the treatment of autoimmune diseases. This program will involve an enhanced systems-level understanding of gene expression and signaling in target tissues from affected end organs and peripheral blood cells.
This page last reviewed on August 1, 2014

Social Media Links